UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 21, 2013

  

THRESHOLD PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

  

Delaware 001-32979 94-3409596

(State or other jurisdiction

of incorporation)

 (Commission File Number)

(IRS Employer

Identification No.)

  

170 Harbor Way, Suite 300
South San Francisco, California 94080

(Address of principal executive offices)(Zip Code)

  

(650) 474-8200

(Registrant’s telephone number, including area code)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 8.01Other Events.

 

On October 21, 2013, Threshold Pharmaceuticals, Inc. issued a press release regarding the announcement of early clinical data from two single-arm, open-label Phase 1 trials evaluating TH-302, an investigational, hypoxia-targeted drug, in combination with antiangiogenic agents for the treatment of advanced solid tumors.

 

The press release is attached as Exhibit 99.1 to this Form 8-K.

  

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits

 

Exhibit 99.1Press release dated October 21, 2013.

 

 
 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

THRESHOLD PHARMACEUTICALS, INC. 

  
       
  By: /s/ Joel A. Fernandes  
   

Joel A. Fernandes 

  
   

Vice President, Finance and Controller 

  
       

Date: October 21, 2013 

      

 

 
 

 

Exhibit Index

 

Exhibit No.    Description                
       
Exhibit 99.1   Press release dated October 21, 2013.